Replies to post #55069 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Hey grizzlyman

I checked previous PR's and did not see in written word a statement from Leo saying cohort7 would commence mid-January. The following is from a Dec9 PR..

Kevetrin: The sixth cohort has completed dosing in the Phase 1 clinical trial of the Company’s anti-cancer drug Kevetrin being hosted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The safety committee is scheduled to meet in mid-December to define the increased dose for the seventh cohort. Maximum tolerated dose of Kevetrin has not yet been reached. Further, Cellceutix has filed an amendment to the trial protocol with the FDA to limit the dosing duration of Kevetrin to six hours. Cellceutix filed the amendment to keep the dosing time frame within a reasonable number of hours as the dosing level increases as the trial progresses.

Unless I missed something. Nothing further mentioned on increased dosing progress.